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Although the last issue of Current Oncology con-
tained a consensus guideline on the management of
anemia in cancer, pressure on our peer review pro-
cess led to an inability to include a timely related
manuscript from Dr. Amanda Goldrick and col-
leagues. I am pleased to rectify that situation in the
present issue. In a retrospective review covering
2002–2003, Dr. Goldrick’s group highlights the rela-
tively low rate of physician intervention in more than
700 cases in which breast cancer patients being
treated in the adjuvant setting became significantly
anemic as a result of their therapy. The rate of inter-
vention involving a discussion (for example) with
patients whose hemoglobin levels were below 90 g/L
was less than half. Nowadays, we realize that a num-
ber of studies describe quality-of-life benefits for
patients who receive support.
Our practice guidelines series continues with an
update on oxaliplatin funding in the management of
gastrointestinal malignancy from Dr. Derek Jonker,
of the Gastrointestinal Cancer Disease Site Group of
Cancer Care Ontario’s Program in Evidence-Based
Care.
A short communication from Dr. Max Dahele and
his colleagues outlines suggested newer management
options for lung cancer, featuring integration in man-
agement strategies by community hospitals and can-
cer referral centres in Ontario. The authors promise
an update once these policies have been fully imple-
mented and tested.
Our guest editorials include a review of the antitumour
activities of statins from Drs. Takahashi and Nishibori, and
a detailed discussion of the role of vaccine therapy in can-
cer from Dr. Jeffrey Schlom and colleagues.
A report—a first for Current Oncology—from the
recent Gairdner Award lectures is likewise included
in this issue. The year 2007 marks the 48th presenta-
tion of the Gairdner Awards, one quarter of whose
past 288 recipients have gone on to win a Nobel Prize
(including two Nobel Laureates presenting lectures
at this year’s symposium).
As 2007 draws to a close, I would like again, as
Editor, to express my gratitude on behalf of the edi-
torial board for your submissions, the efforts of our
publisher, and the support of industry, without whom
we would be unable to continue our work.
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